Navigation Links
U-M scientists find genes that control growth of common skin cancer

Scientists at the University of Michigan's Comprehensive Cancer Center and the National Cancer Institute have identified genes that promote the growth and recurrence of skin cancer. Andrzej Dlugosz, M.D., a professor of dermatology in the U-M Medical School, and colleagues at the University of Michigan and the National Cancer Institute examined the functions of the Hedgehog (Hh) signaling pathway in basal cell carcinoma ?the most common form of cancer ?and uncovered a subset of tumor cells that were resistant to inhibition of the Hedgehog pathway. The new finding has important implications for the treatment of this widespread disease. Their report will be published in the Jan. 15 issue of Genes & Development, but is available now on the journal's Web site.

Basal cell carcinoma (BCC) affects over 1,000,000 Americans each year and frequently develops on sun-exposed sites, such as the face. Surgical removal of BCCs is an effective approach to treating these cancers, which generally have a slow growth rate and seldom spread or metastasize. However, untreated BCCs can cause extensive local tissue damage, and surgical procedures can produce significant scarring in cosmetically sensitive locations, such as the face. The Hedgehog signaling pathway plays a key role in normal development, and its dysfunction has been implicated in a number of different human diseases and neoplasms, including BCCs in skin and cancers arising in brain, lung, prostate, pancreas and other gastrointestinal organs. Dlugosz and colleagues focused on the function of uncontrolled Hh pathway signaling in the growth of BCC. The investigators used genetically engineered mice in which they could manipulate expression of an Hh pathway component, called Gli2 , effectively turning it on or off at will in the skin. As expected, expression of Gli2 resulted in BCC formatio n. In addition, the researchers found that sustained expression of Gli2 is necessary for the continued growth of these tumors. When Dlugosz and colleagues turned Gli2 off, the BCC tumor cells stopped growing and were eliminated by a programmed cell death process. These results are consistent with previous work from other labs studying different Hh-associated tumors, “but we were very surprised to see that some tumor cells persisted after shutting down Gli2 expression,?said Dlugosz. In some of the regressed tumors Gli2 reactivation leads to resumption of BCC tumor growth, suggesting that the residual cell populations may represent BCC tumor stem cells, but Dlugosz cautions that there is as yet no definitive evidence that tumor stem cells exist in BCC. In additional studies, the researchers found that regressing BCC cells could be reprogrammed to differentiate into various epithelial cell types, ultimately capable of assembling fully-formed hair follicles. These results suggest that BCCs contain cells capable of multi-lineage differentiation, similar to normal hair follicle stem cells from which they may arise. If the results of this study are applicable to human BCC, the discovery of residual tumor cells and tumor recurrence may be particularly important given the current efforts to develop Hh pathway inhibitors as a means of combating human BCCs, as well as other cancers. In contrast to other cancer models where inhibition of Hh signaling leads to durable tumor regression, Dlugosz's new work raises the possibility that Hh pathway inhibition in BCCs, while effectively diminishing tumor size, may not be curative due to the survival of this residual tumor cell population. “Our work demonstrates that BCC growth in this model remains strictly dependent on the Hh pathway,?says Mark Hutchin, M.D., a U-M resident in dermatology and lead author on the paper. This is different from many other genetic mouse models of cancer, in which tumor regression following inhibition of an oncogene is frequently followed by the emergence of malignancies that have activated alternative cancer-causing pathways. According to Hutchin, the fact that this does not happen in regressed mouse BCCs suggests that any residual human BCC cells, if present, should also remain in check as long as the Hh pathway is effectively inhibited. Funding for this research was provided by grants from the National Cancer Institute and the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Source:U-M Medical School

Related biology news :

1. Wisconsin scientists grow critical nerve cells
2. UCSB scientists probe sea floor venting to gain understanding of early life on Earth
3. UAB scientists discover the origin of a mysterious physical force
4. Fox Chase Cancer Center scientists identify immune-system mutation
5. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
6. UCLA scientists transform HIV into cancer-seeking missile
7. RNA project to create language for scientists worldwide
8. Carnegie Mellon scientists develop tool that uses MRI to visualize gene expression in living animals
9. To control germs, scientists deploy tiny agents provocateurs
10. Leprosy microbes lead scientists to immune discovery
11. Integration of Agilents MS technology, Proteome Systems software to help scientists in proteomics research

Post Your Comments:

(Date:11/19/2015)... 2015  Although some 350 companies are actively involved ... few companies, according to Kalorama Information. These include Roche Diagnostics, ... market share of the 6.1 billion-dollar molecular testing market, ... for Molecular Diagnostic s .    ... controlled by one company and only a handful of ...
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
(Date:11/12/2015)... Nov. 11, 2015   Growing need for ... tools has been paving the way for use ... of discrete analytes in clinical, agricultural, environmental, food ... predominantly used in medical applications, however, their adoption ... due to continuous emphasis on improving product quality ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... United States ," said Andrew Rae ... advancements regarding iCo-008 are not only value enriching ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide ... Carolina , today announced that the company has set a ... a 391% quarter on quarter growth posted for Q3 of 2014 ... and Mexico , with the establishment of ... December 2015. --> United Kingdom and ...
(Date:11/24/2015)... LEXINGTON, Massachusetts , November 24, 2015 ... Officer, will participate in the Piper Jaffray 27 th Annual ... on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. ... Poulton , Chief Financial Officer, will participate in the Piper Jaffray ... City , NY on Tuesday, December 1, 2015, at 8:30 ...
Breaking Biology Technology: